NPPA Directs Manufacturers To Submit Application For RP Fixation Of New Drugs Through Email Only

Mumbai : For further streamlining the procedure and processing of application in a time bound manner, the National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to submit application online in Form-I for retail price fixation of new drugs.

According to NPPA, with effect from April 1, 2021, no application in Form-I for retail price fixation of new drugs in physical form shall be accepted by NPPA. The application in Form-I for retail price fixation of new drugs shall be accepted through email id only at pricing-nppa@gov.in as mentioned in para 2 of office memorandum (OM) dated August 26, 2020.

NPPA had mooted a proposal last year in August 2020 to develop an online system for disposing and monitoring of applications filed under various provisions of DPCO-2013 towards ease of doing business.

According to a NPPA notice, “The manufacturers have been directed to refer to NPPA’s OM dated August 26, 2020 regarding development and implementation of ecosystem for timely disposal and monitoring of various applications filed with NPPA’ wherein it was observed that most of the new drug applications are received online which has helped in their faster processing in a time bound manner.”

Development and implementation of an ecosystem for timely disposal and monitoring of various applications filed under various provisions of DPCO, 2013 includes submission of Form-I for application for the pricing of new drugs.

NPPA has stipulated that the applicant companies need to submit the application with all requisite documents via email at pricing-nppa@gov.in.

It has also stipulated pharma companies to Form-l related to revised prices for scheduled formulations, Form-II related to quarterly return in respect of production/import and sale of NLEM Drugs and Form-V related to price list.

Pharma companies should submit these forms on Integrated Pharmaceutical Database Management System (IPDMS) within the prescribed timelines. Besides this, the application for the discontinuation of the production of scheduled formulation with all requisite documents should be sent via email at monitoringnppa@gov.in.

Applications for special price for packaging under paragraph 11(3) of DPCO 2013 can be submitted at pricing-nppa@gov.in.

As per NPPA recommendations, NPPA authority meeting would be preferably held every month. If due to certain circumstances the same could not be held in a particular month, the authority meeting would be held in subsequent months as per requirement. Meeting of the multidisciplinary committee of experts would be held prior to the authority meeting.

All Indian pharma manufacturer associations should upload the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) on their website including the detailed procedure mentioned in paragraph 10 of the UCPMP regarding lodging of complaints.

A quarterly report mentioning details of the complaint received and the decision taken thereon should be submitted by the concerned association to NPPA within 30 days of the end of the quarter via email to monitoring-nppa@gov.in.

NPPA has also stipulated timelines for disposal of applications in different categories like in Form I which is related to new drug prices and the given timeline is within 60 days.

Form II is used for the revised prices of scheduled formulations and the stipulated timeline to file is within 15 days from the date of notification. Form III is applied for the purpose of quarterly returns in respect of production/import and sale of NLEM drugs and the set timeline for the manufacturer is within 15 days from the date of the end of quarter.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/02/Form-I-OM-160221080633.pdf”]

Related Posts

  • Pharma
  • April 25, 2024
  • 60 views
Regular Supplier Of Stents Ignored By Doctors Due To Low Commission; Company Supplying Despite Crores Of Dues

THIRUVANANTHAPURAM: Although the agencies have stopped the supply of cardiac surgery materials including stents to government hospitals, the doctors are ignoring the company that still provides the materials without delay.…

  • Pharma
  • April 25, 2024
  • 106 views
ACB Gujarat Nabs Female Drug Inspector In A Bribe Case

Ahmedabad: The Anti-Corruption Bureau (ACB) of Gujarat today nabbed a Drug Inspector of the Food and Drug Control office in the city in a bribery case involving a sum of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Regular Supplier Of Stents Ignored By Doctors Due To Low Commission; Company Supplying Despite Crores Of Dues

Regular Supplier Of Stents Ignored By Doctors Due To Low Commission; Company Supplying Despite Crores Of Dues

ACB Gujarat Nabs Female Drug Inspector In A Bribe Case

ACB Gujarat Nabs Female Drug Inspector In A Bribe Case

Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

India Lifts Safeguard Measures On Isopropyl Alcohol Imports

India Lifts Safeguard Measures On Isopropyl Alcohol Imports

Punjab And Haryana HC Notice To Centre On Petition Against Misuse Of Oxytocin

Punjab And Haryana HC Notice To Centre On Petition Against Misuse Of Oxytocin

Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines

Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines